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Abstract 
Background: Human infection studies (HIS) are valuable in vaccine development. 
Deliberate infection, however, creates challenging questions, particularly in low and 
middle-income countries (LMICs) where HIS are new and ethical challenges may be 
heightened. Consultation with stakeholders is needed to support contextually 
appropriate and acceptable study design. We examined stakeholder perceptions 
about the acceptability and ethics of HIS in Malawi, to inform decisions about 
planned pneumococcal challenge research and wider understanding of HIS ethics in 
LMICs. 
Methods: We conducted 6 deliberative focus groups and 15 follow-up interviews 
with research staff, medical students, and community representatives from rural and 
urban Blantyre. We also conducted 5 key informant interviews with clinicians, ethics 
committee members, and district health government officials.   
Results: Stakeholders perceived HIS research to have potential population health 
benefits, but they also had concerns, particularly related to the safety of volunteers 
and negative community reactions. Acceptability depended on a range of conditions 
related to procedures for voluntary and informed consent, inclusion criteria, medical 
care or support, compensation, regulation, and robust community engagement. 
These conditions largely mirror those in existing guidelines for HIS and biomedical 
research in LMICs. Stakeholder perceptions pointed to potential tensions, for 
example, balancing equity, safety, and relevance in inclusion criteria.  
Conclusions: Our findings suggest HIS research could be acceptable in Malawi, 
provided certain conditions are in place. Ongoing assessment of participant 
experiences and stakeholder perceptions will be required to strengthen HIS research 
during development and roll-out. 
Keywords: Human Infection Studies, pneumococcal, Malawi, acceptability, ethics  
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1 Background 
Human Infection Studies (HIS), sometimes referred to as human challenge studies, 
involve deliberately infecting healthy adult volunteers with a microbial pathogen, 
such as malaria parasites or typhoid bacteria. HIS are often used for vaccine testing, 
with volunteers vaccinated before infection to test potential vaccine candidates. HIS 
can be conducted much more rapidly and with far smaller sample populations than 
standard efficacy trials, which means HIS can accelerate vaccine development [1, 2]. 
HIS science has contributed to new vaccines in several areas, including typhoid and 
malaria [2–4]. While HIS have been conducted for decades in High-Income 
Countries (HICs), they are much newer in Low and Middle-Income Countries 
(LMICs) [2, 3]. The highest burdens of vaccine-preventable disease are found in 
LMICs, and different biological and environmental conditions, including population 
genetics and pathogen strains, mean findings from vaccine trials in high-income 
settings do not always apply [5]. Consequently, conducting HIS in LMICs holds the 
potential to help develop effective vaccines for these populations.   
The deliberate infection involved in HIS science creates challenging questions for 
ethical practice and community engagement [6, 7]. Challenges are particularly 
apparent in LMICs. For example, informed consent and fair compensation are 
complex in contexts of limited research experience and high poverty; health systems 
may lack adequate facilities to monitor and treat adverse events, and regulatory 
guidelines may be limited [2, 4, 8–10]. The growing literature on HIS ethics suggests 
a range of ethical principles, including a strongly justified research question that can 
only be answered through HIS, independent review, qualified and experienced 
researchers, rigorous informed consent, safe selection of participants, minimisation 
of risks and no irreversible harm, protection of contacts and the environment, 
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compensation that avoids undue influence, compensation for harm, and public 
involvement [4, 6, 8]. However, further evidence is needed to guide researchers and 
ethics committees on appropriate frameworks for HIS, particularly in LMICs [10, 11].  
Stakeholder consultation to generate evidence on effective and acceptable 
approaches can help to inform ethical guidance and immediate HIS study design [2, 
8, 12]. Such consultation can provide insight for critical decisions such as inclusion 
criteria, recruitment, informed consent, and comprehension testing, residential stays, 
compensation, withdrawals, and community engagement [4, 13]. 
1.1 Undertaking HIS in Malawi 
The Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW) is 
planning Streptococcus pneumoniae HIS in Malawi (the Malawi Accelerated 
Research in Vaccines using Experimental and Laboratory Systems project, or 
(MARVELS)) [14]. This project builds on over a decade of pneumococcal HIS 
research at the Liverpool School of Tropical Medicine (LSTM), UK, and is predicated 
on the need for new pneumococcal vaccine in Malawi as current vaccines do not 
create herd immunity [15]. Streptococcus pneumoniae (pneumococcus) is a bacterial 
pathogen commonly found carried in the nose. If the pneumococcus spreads to the 
lungs, blood, or brain, it causes serious infection, including pneumococcal 
pneumonia, sepsis, and meningitis, respectively [16, 17]. In Malawi, pneumococcus 
is found in 90% of all children’s noses and 40% of adults with Human 
Immunodeficiency Virus (HIV) (10-20% adults without HIV) [15, 18, 19]. The project 
conceives a series of HIS, starting by establishing the feasibility of carriage in 12-36 
participants. If effective, the project would move to further stages of vaccine testing, 
scaling up to around 150-400 participants per study depending on the stage and 
study focus. Volunteers would be exposed to pneumococcus through a saline 
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solution dropped into the nose, and closely monitored for safety. Given uncertainties 
around participant contact and hospital access, a three-day residential stay is 
planned for volunteers following inoculation. The provided accommodation to 
participants is located in close proximity to one of Blantyre’s large private hospitals. 
To reflect on the implications of undertaking HIS in Malawi, MLW and partners 
organised a workshop on the potential and challenges of HIS in Malawi in 2017. This 
workshop brought together government stakeholders, ethics committee members, 
and researchers, including people with experience of conducting and regulating HIS 
elsewhere in Africa and in HIC [2]. The workshop identified a need for community 
consultation to understand the acceptability and ethics of HIS in the Malawi context. 
This study responds to this recommendation.  
1.2 Aims of this study 
Our immediate aim in conducting the research reported in this paper was to generate 
evidence on stakeholder perceptions and preferences that could inform MLW’s 
decisions about whether to proceed with HIS in Malawi and, if so, on MARVELS 
design and implementation. While the MARVELS team felt HIS had considerable 
potential for benefit in Malawi, a decision to apply for permission to conduct a 
feasibility study depended on knowing whether or not HIS would be welcome and 
socially appropriate. Approvals for pneumococcal HIS feasibility are still pending. 
The data presented in this paper were included in the ethics submission to support 
their review. We also aimed to support the wider development of ethical frameworks 
for HIS science in Malawi and other LMICs through information on stakeholder 
perceptions of ethical challenges and potential approaches in this context.  
In considering the acceptability of HIS, we were interested in a definition of 
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acceptability that involves more than tolerance [20]. MLW’s aim is that communities 
and other stakeholders should feel highly positive about HIS research in Malawi, 
seeing HIS as relevant and ethical, rather than just allowing HIS to take place. We 
wanted to find out whether pneumococcal HIS would be seen as worthwhile and 
ethical and how HIS could be designed to ensure it met stakeholder standards, 
expectations, and the highest ethical standards. 
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2 Methods 
We used Focus Group Discussions (FGDs) and individual interviews to examine 
stakeholders’ perceptions and opinions on the acceptability and ethics of HIS 
research in Malawi.  
We conducted 6 deliberative FGDs [21] with MLW frontline research staff, medical 
students, and three sets of community representatives: chiefs (local community 
leaders), religious leaders, and members of MLW’s Community Advisory Group 
(CAGs). Frontline research staff included research nurses and fieldworkers, and we 
focused on staff involved in vaccine and other clinical trials that involved some 
procedures that would be used in pneumococcal HIS (e.g., nasal samples, health 
screening, and in-patient stays). The CAGs comprise representatives of active 
community-based organisations located in rural or urban Blantyre. CAG members 
were elected by their communities, and their main role is to advise MLW on 
appropriate engagement with communities for research. The chiefs and religious 
leaders involved in this study had no previous official engagement with MLW but 
were aware of MLW’s existence. In addition, some of these community leaders had 
previously participated in research conducted by other research institutions.  
To allow participants to reflect and share considered perspectives, we conducted 
Follow-Up Interview (Fup) after 2-3 weeks with 3 participants from each FGD to 
identify any change in views or further reflections. We selected participants for 
follow-up interviews based on the opinions contributed in FGDs and level of 
participation, focusing on those who had expressed particularly critical or cautious 
views that we wanted to explore further, those expressing their views most strongly, 
and participants who had spoken little during group discussions. This strategy 
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proved useful for ensuring we did not misinterpret original strong opinions and 
gathered views from those less confident to speak in a group setting.   
We also conducted 5 Key Informant Interviews (KII) with a combination of Research 
Ethics Committee (REC) members, senior clinicians at the hospital where 
pneumococcal HIS (MARVELS) would take place, and district health management 
officials. The sample of participants is shown in table 1. In later FGDs and interviews, 
no new issues emerged, so we concluded that data saturation had been reached 
and ended data collection [22]. 
Table 1: stakeholders for FGDs, follow up interviews and key informant interviews 
Method Stakeholder group Number of participants 
Focus group 
discussion 
Frontline researcher staff (research 
nurses and fieldworkers) 
9 (2 FGDs, one with 4 and one with 
5 participants) 
(9 females, 1 male) 
Community Advisory Group (CAG) 
members (Blantyre urban) 
10 (5 females) 
Chiefs (Blantyre rural) 10 (4 females) 
Religious leaders (Blantyre urban) 10 (1 female) 
Medical students 10 (4 females) 
Post-FGD 
follow-up 
interviews 
with a sample 
of FGD 
participants  
Frontline researcher staff 3 (All females) 
CAG members 3 (2 females) 
Chiefs 3 (2 females) 
Religious leaders 3 (1 female) 
Medical students 
3 (1 female) 
In-depth Research ethics committee (REC) 2  
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interview members 
Senior clinicians  2  
District health management officials   1  
Total 69 (33 females) 
 
2.1 Data collection procedures 
Interviews and focus groups used a semi-structured topic guide (Additional File) with 
open-ended questions about views on HIS, including perceived benefits and 
concerns, particular procedures (such as inclusion criteria, compensation, and safety 
measures), the types of HIS that would be acceptable in Malawi and the overall 
ethics of HIS. As HIS research had not yet been conducted in Malawi, we anticipated 
that few, if any, FGD and interview participants would have heard of HIS or be 
familiar with HIS procedures. To ensure participants could give views based on 
some understanding of HIS, we provided information on HIS during each FGD and 
interview and encouraged participants to ask questions if they wanted more 
information. This approach drew on ideas of deliberate discussion, used in empirical 
ethics research to uncover participants’ informed, considered, and collective views 
on a normative question [23]. Information on the general HIS approach was provided 
at the start, and more specific information about the potential MARVELS plan and 
pneumococcal HIS was provided later once participants had given initial views. In 
addition, further information was provided as needed in response to questions from 
participants or where we noticed misconceptions about procedures that would be 
involved (e.g., that children would be enrolled, that the residential stay would involve 
quarantine, or that HIS would help the development of treatment rather than 
vaccine).  
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We were conscious that the views expressed by stakeholders would be heavily 
influenced by the information we provided. We wanted to avoid describing HIS in a 
way that only emphasised benefits and discouraged any critical views, but we were 
also cautious about creating fear and rumours based on misunderstandings (e.g., if 
we did not discuss planned procedures for safety). To balance this, we sought to 
present information neutrally and to focus on procedures that would be involved in 
HIS and documented experience in relation to safety (e.g., plans for a residential 
stay, and the number of severe adverse events recorded in LSTM). The information 
provided was developed through discussion among the study team. To encourage 
openness and reduce courtesy bias, we highlighted that there are different views 
about whether HIS is acceptable, that there was uncertainty about appropriate 
procedures, and that the MLW team needed stakeholder feedback and guidance. 
We also emphasised that the social scientists primarily responsible for conducting 
the interviews and FGDs were not part of the main MARVELS team. One of the 
MARVELS scientists who had worked on HIS in LSTM (KJ or JR) was involved in 
part of 4 FGDs to explain the detailed MARVELS procedures and answer questions 
from participants. We were conscious that their involvement might increase courtesy 
bias but decided it was important to explain additional details for participants and 
found that participants appreciated the opportunity to ask questions directly of people 
who had been involved in HIS in the UK. For FGDs where these scientists were 
involved, we allowed time, after they had left for further discussion, in case 
participants, were more reluctant to share critical views with the HIS scientists 
present.  Follow-up interviews provided a further opportunity for participants to share 
any views they may have been reluctant to express in front of those involved more 
directly in HIS. This combination of deliberative FGDs and follow-up interviews has 
 Page 11 of 49 
been effective for similar ethical topics in similar contexts [24]. 
FGDs with community representatives were conducted at a neutral venue, while 
follow-up interviews were held at places chosen by participants (their homes or 
workplaces). For MLW staff and medical students, FGDs and follow-up interviews 
took place at the MLW office in Blantyre, as the MLW setting is more familiar for 
these groups and so less likely to discourage open discussion. All KIIs took place at 
participants’ workplaces.  
2.2 Data processing and analysis  
All FGDs and interviews were audio-recorded and transcribed, and those conducted 
in Chichewa were translated into English.  
The analysis was ongoing during fieldwork, using an iterative approach to identify 
emerging themes that could be clarified or explored further through later data 
collection. We conducted thematic coding in NVivo using broad deductively defined 
themes (such as views on inclusion criteria or perceived benefits of HIS) and 
inductively derived sub-themes (such as impacts on household members or 
population benefit). We also used framework matrices to compare perspectives 
between different stakeholders. Two researchers (KG and BK) worked together on 
coding to compare interpretations and agree on a coding framework.   
2.3 Ethical approval 
The study received ethical approval from the Liverpool School of Tropical Medicine 
and Malawi College of Medicine Research Ethics Committee. We sought permission 
from Principal Investigators at MLW and the College of Medicine to speak to frontline 
research staff and medical students, respectively. All participants received written 
information sheets and verbal explanations and gave written consent. 
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3 Results 
In this section, we present our findings under three broad headings. First, we 
describe stakeholders’ views on the acceptability of pneumococcal HIS, including 
perceived benefits, concerns, and views about whether overall pneumococcal HIS 
might be acceptable and ethical in Malawi. Second, we report stakeholders’ 
suggestions on the requirements for pneumococcal HIS to be acceptable, including 
appropriate models of consent, a fair selection of research participants, and the 
availability of medical support. Third, we describe views on HIS for other diseases 
beyond pneumococcus, to consider the acceptability of HIS that require different 
procedures. 
3.1 Views on the acceptability of pneumococcal HIS research in Malawi 
3.1.1 Perceived benefits of HIS 
All stakeholder groups saw potential benefits of pneumococcal HIS research in 
Malawi, centred on the potential to improve population health. Within this, key issues 
included the high burden of pneumococcal disease and the value for a vaccine 
suited to the Malawi population.  
In relation to pneumococcal disease, almost all stakeholders focused on pneumonia 
rather than other types of pneumococcal disease (only medical students mentioned 
sepsis). Stakeholders noted the high incidence and severity of pneumonia disease 
and suggested that developing a vaccine would protect people from ill-health.  
“I think it is welcome because pneumonia takes a lot of lives […] a vaccine to 
prevent pneumonia is really needed.” (Religious Leader, FGD6) 
A vaccine developed specifically for the Malawi context was considered valuable 
given differences in genetic background and environmental context.  
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“It’s indeed right to conduct the research […] the drugs we have here were 
developed in Europe and maybe because of differences in climate and our 
bodies; those drugs don’t work here” (Chief, FGD4) 
“These studies have been done in a setting like the UK, but it’s different from 
here, isn’t it? Here there is a number of things such as genetic and 
environmental factors that may have a bearing on how people respond to 
pathogens” (Senior clinician, KII)   
While many stakeholders mentioned these benefits, some raised questions about 
the potential value of HIS research. In particular, while community participants 
seemed confident that HIS would deliver solutions for population health, a few key 
informants expressed uncertainty about the likely impact of pneumococcal HIS, 
perhaps reflecting awareness of both the unpredictability of research and the need to 
prioritise among competing research agendas.  
“I am just interested to know why you want to do a HIS study on 
pneumococcus now in Malawi. We know that yes, streptococcus pneumoniae 
is a big problem, […], so what’s changed for this to come up now? […] what 
will be its impact?” (Senior clinician, KII) 
3.1.2 Perceived concerns about HIS 
While stakeholders saw HIS as having potential benefits, they also had concerns. 
Key issues emphasised by all stakeholder groups were safety and community 
reactions. 
3.1.2.1 Participant safety  
On safety, the deliberate infection was initially perceived as carrying significant risks 
by many stakeholders. However, when we explained the focus on pneumococcal 
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carriage (that is, only observing ability of the bacteria to live in the nose rather than 
causing pneumonia or other pneumococcal diseases), the prevalence of carriage 
and that there is low rate of adverse events in similar HIS in the UK, many 
stakeholders were reassured about safety. 
“If you are just monitoring whether someone has it in their nose without it 
necessarily affecting that person, then you aren’t causing any harm for people 
to be scared” (Religious leader, FGD6-Fup) 
“I don’t think it will have any risks and I don't think it’s as intense as I thought 
before […] with how you have explained that you’re just looking at carriage, I 
think it’s safer” (Frontline research staff, FGD1-Fup)  
Nevertheless, safety concerns remained among some stakeholders, particularly 
those involved in medical care and research. Key issues were the unpredictability of 
individual biological reactions to the pneumococcus and limited healthcare facilities 
to manage severe adverse events in Malawi.  
“People react differently to those agents, maybe because of their difference in 
biology, so just in case someone experiences the infection, and dies, […] so 
as researchers, how prepared are you to handle such…?” (Medical student, 
FGD5-Fup) 
“Obviously you would want to do it in a setting whereby if a participant is sick, 
you are able to give all the treatment that is necessary, such as High 
Dependency Unit care or Intensive Care Unit. But in Malawi it’s a bit tricky 
because we already struggle with resources to take care of patients that are 
very sick.” (Senior clinician, KII) 
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Even when participants felt procedures were largely safe, some were concerned 
about the psychological impact of participation in HIS related to fear of infection. 
“That psychological part of knowing for sure I have been infected - I think they 
could not interact normally or be as productive as they could, because they 
would have that psychological mind-set that ‘I may be sick, let me restrict 
myself’.” (District Health Management, KII)  
3.1.2.2 Negative community reactions 
Partly linked to this concern about fear, all stakeholder groups expressed concern 
about negative community reactions to HIS, believing communities would see HIS 
research as high-risk and that misconceptions and rumours were likely. For example, 
participants mentioned the potential for rumours about the purpose of deliberate 
infection, links to witchcraft, and the intentions of non-Malawian researchers, 
particularly because MLW may be seen as a foreign institution. 
This concern about community reactions partly reflected the context of recent 
rumours around ‘bloodsucking’ in Malawi: in 2017, there were widespread rumours 
about bloodsuckers, with related community violence and some disruption to 
community-based research [25, 26]. This recent experience heightened sensitivity to 
potential community distrust: 
“There are concerns, people don’t trust their fellow humans. [or] believe that 
an organisation has come to help, for example, the issue of bloodsuckers. So 
to just enter a village without proper communication, I tell you - you can be 
chased away.” (Religious leader, FGD6) 
Potential community distrust of HIS was seen by all stakeholder groups as likely to 
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limit the recruitment of HIS volunteers. 
“Recruiting participants could be a problem in most communities due to 
misunderstanding the information and not completely trusting the people who 
conduct the research.” (Religious leader, FGD6) 
In addition, frontline researchers saw the potential for rumour as carrying risks for 
MLW’s reputation and for the safety of frontline staff in other studies.  
“For those who go into the community, like the field workers, or even the 
hospital based research staff, their security and safety […] have you thought 
about the safety?” (Frontline research staff, FGD2) 
“We are trying hard to build…we have established community trust, of which 
we can say that we are not 100% good; we have got some areas where we 
are also lacking, and we are trying hard to maintain that. So, bringing in HIS 
[…] we might end up ruining the trust that people have” (Frontline research 
staff, FGD2) 
3.1.3 Reflections on the overall acceptability of pneumococcal HIS 
As illustrated in the previous sections, many participants described both benefits and 
concerns around pneumococcal HIS. To understand overall acceptability, 
participants were asked whether they thought HIS research should go ahead in 
Malawi. Most felt HIS would be acceptable provided researchers addressed certain 
important conditions (conditions we explain below). Views ranged from high levels of 
enthusiasm to more uncertainty but with willingness to consider that HIS could be 
appropriate. 
“Had it been there were these studies done before, maybe I would have said 
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‘Yeah it’s OK, this can be done’. But…I am on the 50-50, yes or no because 
it’s the very first time and I am thinking ‘how are they going to handle issues of 
safety?’” (REC member, KII) 
“As a Malawian citizen I believe this research is really necessary, because 
people in our country are struggling […] in our hospitals, doctors try to save 
lives but lives are being lost. Now researchers have suggested new methods 
that can be tried to save lives.” (CAG member, FGD3-Fup) 
Positive overall views of HIS were often related to the awareness that many existing 
medicines were developed through research with a few people for later public use. 
Research was therefore considered a normal and necessary step to improving 
population health, and so acceptable even if it may involve risks and burdens for 
some individuals. 
This same idea of benefit for the greater good was reflected in discussions explicitly 
about the ethics of HIS, and specifically whether HIS research would meet principles 
of justice and ensuring a ‘fair offer’ for participants, with risks and burdens of HIS 
adequately balanced by the benefits [27]. Many stakeholders emphasised that some 
risk or burden for participants was outweighed by the potential for population health 
benefit, or discussed the positive aim behind HIS: 
 “I feel it is a fair thing … you would get vaccines developed quickly from a 
small number of volunteers which can benefit the population […] so I feel like 
it has all those benefits that could outweigh the negative parts.” (District health 
management, KII) 
Some staff, community leaders and medical students shared these sentiments. 
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However, views here varied, and a few stakeholders were concerned about lack of 
individual benefit: 
“It sounds to me like the benefit is more for the study than the participants, I 
can’t see what they have to benefit, rather than contributing to whatever 
vaccine may be developed in the long term.” (Senior Clinician, KII) 
To promote an adequate balance of benefits and burdens, participants identified a 
range of conditions and procedures needed to address concerns around safety and 
community reactions and ensure pneumococcal HIS was ethical and acceptable. 
These conditions are discussed below. 
3.2 Conditions required for the acceptability of pneumococcal HIS 
As reported in the previous section, views on the ethical acceptability of 
pneumococcal HIS in Malawi were sophisticated and varied, suggesting that HIS 
might be acceptable under some conditions but not others. In this section, we report 
on stakeholders’ views on what they considered to be the requirements for ethical 
and acceptable pneumococcal HIS.  
3.2.1 Voluntary and informed consent 
All stakeholder groups highlighted voluntary and informed consent as a key condition 
affecting the acceptability of HIS. The priority placed on informed consent was 
evident in a discussion about whether a pneumococcal HIS as MARVELS was just 
and constituted a ‘fair offer’ for participants. Those stakeholders who viewed the 
MARVELS study as ethically acceptable often emphasised the informed, voluntary 
consent process as a basis for this judgement. 
“That is justice because the participant will be informed; they have got the 
information and volunteered. If someone is volunteering, it means there is 
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justice between you and them.” (Chief, FGD4-Fup)   
“A good and thorough information I think will balance [the benefit and burden], 
where they will get the right information, and it has to be exactly what is going 
to happen.” (REC member, KII) 
As these quotes show, discussion about informed consent emphasised both full 
understanding and voluntary decision making. Both aspects would be expected in 
most health research, but participants emphasised that explanations should be 
particularly clear and open with HIS, given concerns about community 
misconceptions, perceived potential for risk from deliberate infection, and complexity 
of information.   
“They really need people who have got a strong understanding of things […] 
this time we are actually introducing a foreign body in the human body, right? 
So, this thing, it needs somebody to have a clear type of understanding.” 
(Frontline Research staff, FGD2) 
While the overall emphasis was on transparency, a small number of participants 
raised concerns that the initial description of HIS procedures might cause alarm if 
handled badly. One CAG member, for example, suggested that people should not be 
told that HIS involved introducing bacteria as people would see this negatively, 
although other CAG members disagreed and emphasised the need for openness. 
One medical student expressed uncertainty about how to balance openness and 
avoiding concern, given that the idea of being infected may cause fear: 
“We want the person to be informed, but then I think we need to be careful 
with these details because we may end up scaring people. […] I don’t know 
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how we can put it because we need to find a balance between keeping them 
informed and then not scaring them away, because it’s really scary.” (Medical 
Student, FGD5-Fup)  
Involvement of family members in consent was discussed by many stakeholders, 
reflecting a concern not to harm family relationships or household livelihoods and 
dominant norms around permission from family members, particularly for women. 
Again, enabling discussion with family is standard practice for consent in health 
research, but it was particularly emphasised for MARVELS because the planned 
three-day residential stay would take participants away from home  
“People at home are supposed to agree with you so they are aware where the 
participant is and what is happening.” (CAG member, FGD3) 
Scope for withdrawal was also an aspect of consent with more specific implications 
in HIS research. Some medical students and research staff raised questions about 
permission to withdraw, given the need to take antibiotics to clear any infection and 
saw this permission as important for voluntary consent.  
“Maybe the person has volunteered himself, and then you have injected, you 
have started medications, maybe the medications are supposed to run maybe 
for the week. And then in the consent we have a part where it says the person 
can accept but at any time can withdraw. What if the medications haven’t yet 
finished, but the person maybe didn’t understand, and says I can’t continue, 
and you can’t say “no you have to, you have to!” What can happen in that 
situation?” (Frontline Research staff, FGD1) 
Research staff felt safety and the right to withdraw could be balanced through 
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sufficient explanation and ensuring participants fully understood planned procedures: 
“We will explain to them that we will give you the bacteria and after that we 
will see if it can go by itself, but if it doesn’t and you have fever or whatever, 
we will be giving you some medication. So, if you withdraw, maybe if 
something can happen at home, there will be no problem. You can get this 
medication if you are not willing to continue.” (Frontline Research Staff, 
FGD1-Fup)   
The perceived importance of informed and voluntary consent had implications for 
views about acceptable recruitment approaches. The MARVELS team was 
considering using flyers or adverts distributed through places such as college notice 
boards or social media, with phone numbers to contact for further information. 
Stakeholders welcomed this approach as avoiding pressure to take part (perhaps in 
contrast to the more typical of face to face recruitment in communities). 
“I support the flyers, they are really good because when one reads it properly, 
they will be able to make a decision to say ‘aaah, I think I should take part in 
this research’, because they will read everything for themselves unlike just 
being told.” (CAG member, FGD3-Fup) 
“I think it [use of flyers] will be of advantage, because people will come on 
their own will, we'll not coerce them to join the study.” (Frontline Research 
staff, FGD2-Fup)  
Beyond specific procedures for recruitment and consent, the value placed on 
informed and voluntary participation also affected views on other procedures, 
particularly inclusion criteria and compensation, as discussed below. 
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3.2.2 Fair selection of participants  
Inclusion and exclusion criteria for HIS participants were seen as an important 
consideration for acceptability among all stakeholder groups. Participants in focus 
groups and interviews were asked openly about criteria they saw as important and 
for their views on criteria being considered by the MARVELS team. Views on groups 
of who should be either targeted for participation or excluded reflected concerns 
related to informed and voluntary participation, community interest and 
misconceptions, equitable opportunities for participation between different population 
groups, burden on livelihoods or other activities, and ensuring research value and 
validity through a sample population considered relevant and unbiased - principles 
that were sometimes in tension. 
The health status of HIS participants was raised by all stakeholder groups as an 
important consideration. Stakeholders recommended excluding people with long-
term or acute conditions that might increase vulnerability to pneumococcal infection, 
as well as people allergic to the antibiotics used to clear the infection and those with 
other contraindications. They urged thorough screening, particularly because 
potential volunteers may be unaware of underlying conditions. 
“I would be worried about […] people who have diseases that would lead 
them to be vulnerable to any sort of infection. So, people who have chronic 
comorbidities like a heart failure patient or somebody with chronic renal 
dysfunction.” (Senior clinician, KII) 
“I think this research is suitable for someone who has been screened, 
someone who has no health problem, so that when they are infected, their 
body will easily fight the infection.” (CAG member, FGD3) 
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Views on inclusion of people with HIV were mixed, with concerns for safety but also 
for equity and relevance of the findings for a high-risk group. Many felt people with 
HIV should be excluded due to vulnerability to infections. However, some also 
discussed the need to ensure any resulting vaccine to be suitable for people with 
HIV, given their susceptibility to pneumococcal infection. 
“This vaccine is not only going to those who are HIV negative, […], so don’t 
you think that we will also need to study those who are on ART, if we give 
them this vaccine, how is it going to work? Or like are we not leaving them 
aside? (Frontline research staff, FGD1)  
As one way to balance these concerns for safety, equity and relevance, senior 
clinicians felt people with HIV might potentially be included if they were virally 
suppressed, though they felt more information was needed to make this decision: 
 “In my view, I don’t necessarily see that as a severe contraindication, if we 
have evidence that they have an undetectable viral load, but I don’t know” 
(Senior Clinician, KII) 
Beyond criteria around health, stakeholders discussed three criteria under 
consideration by the MARVELS team: restricting participation to medical students, 
people fluent in English, and those with higher levels of education. The MARVELS 
team proposed these criteria to ensure potential participants could fully understand 
study information and to facilitate discussion with MARVELS clinicians, some of 
whom are British and without fluent Chichewa. Stakeholders saw potential benefits 
of these criteria for informed consent, and some supported restricting participation to 
these groups. 
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“I think the idea of involving medical students will be better because 
considering the…. understanding the concept, it’s easier for us (medical 
students), but for people out there it’s not going to be easy.” (Medical student, 
FGD5) 
However, many stakeholders thought focusing only on these groups would be 
inequitable and deny opportunities for participation to others.  
“If we say that participants should be determined by a certain level of 
education, we are being biased. Someone may be able to understand but not 
be educated to the standards you want.” (Chief, FGD4) 
A further concern was that restricting participation might affect community views of 
the relevance of the research if participation was later expanded, or of the resulting 
vaccine. 
“If you focus only on educated people, there will be a lot of questions around 
equity, whether the findings can be trusted, safety of volunteers and being 
unsure if the research has even started. It would be better to recruit some 
educated and some uneducated people, so the results represent both sides.” 
(CAG member, FGD3-Fup) 
To address these concerns, some suggested broadening the sample, and involving 
Malawian clinicians in the research team or using translators to enable 
communication, as they had seen with other studies or in hospitals where translators 
assist English-speaking clinicians.  
3.2.3 Adequate medical care  
Medical support to ensure participant safety was viewed as critical for the 
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acceptability of pneumococcal HIS research in Malawi. Key discussions related to 
the provision of adequate healthcare, the planned residential stay, and other 
measures designed to ensure safety. 
3.2.3.1 Healthcare facilities 
Stakeholders emphasised the need for high-quality healthcare facilities and 
procedures of the same standard as those in HIC: 
“The standard should be better than the ones used in Liverpool, because in 
Liverpool obviously they have more resources for controlling […] let’s say 
things get out of hand, as compared to here, we do not have a lot of 
resources that can help us to control. So, monitoring will have to be of the 
best standard.” (Medical student, FGD5) 
Participants also emphasised the importance of adequate laboratory facilities and 
experienced staff with the skills to support volunteers if they develop an infection. 
These technical and ‘backroom’ aspects were mentioned particularly by stakeholders 
from medical and research settings. 
“It’s fine to do it but after we have made sure that everything is in place, we 
have a laboratory that is of high quality, the inoculum will be kept there safe, 
we have the expertise.” (Senior clinician, KII)  
As well as staff with experience in HIS and pneumococcus, some participants 
mentioned the need to involve local staff for both, building research capacity and 
because of their existing trust by participants. 
“You need to include local clinicians. Clinicians who are well known by people 
and who also should develop skills in carrying out that type of study.” (REC 
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member, KII) 
3.2.3.2 Residential stay 
As previously described, the MARVELS team plans a three-night residential stay for 
participants following inoculation at an accommodation that is located in close 
proximity to one of Blantyre’s private hospitals. This residential stay was generally 
welcomed by stakeholders as important for safety, allowing easy access to medical 
care and the research team. 
“It’s good you thought of arranging the residential stay to protect participants, 
because they will be close to Mwaiwathu hospital (private hospital in 
Blantyre). It will be safe for participants.” (Chief, FGD4) 
However, while the residential stay was welcomed for medical support, there were 
some concerns about the impacts on household members left behind, and 
community participants in particular worried about the impact on livelihoods if the 
breadwinner is away from home. Some participants also mentioned that people may 
dislike being away from home or feel trapped in the hostel.  
Views on an alternative non-residential option were mixed. Some felt this could not 
be considered for initial HIS studies, but others felt a non-residential option should be 
allowed, particularly if volunteers live close to the hospital or have good transport 
and communication access in case of adverse events. 
“I think if the person stays in the city or has a car, it won’t be difficult; if they 
face any problem, they can rush to the hospital straight away.” (CAG member, 
FGD3-Fup) 
3.2.3.3 Additional safety measures 
Several additional measures were proposed by the MARVELS team as part of a 
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package of medical support, largely following procedures used with pneumococcus 
HIS in the UK. This included providing an emergency package of antibiotics and a 
thermometer so that participants could take their temperature daily to monitor 
reactions to inoculation and treat themselves in case they could not access medical 
care in an emergency. Stakeholders generally saw this package as useful. However, 
many raised concerns about limited understanding of thermometer use and improper 
use of antibiotics, particularly among volunteers with less education or no medical 
training.  
“If it’s the medical students then it’s OK, but if it’s not, it’s better they just come 
to be checked […] if he is not that well educated, if they just feel a fever, you 
are not sure that they will actually take the drugs as they have been 
advised…some may even overdose.” (Frontline Research staff, FGD2-Fup) 
“Our friends in the UK are more advanced; they know how to use a 
thermometer, whereas someone from Malawi doesn’t know how it’s properly 
used.” (CAG member, FGD3-Fup)  
To address this potential for misunderstanding, stakeholders suggested clear 
explanations for HIS volunteers about how and when to take the drugs, or follow-up 
visits at home by the research team to monitor antibiotic use.  
Other medical support procedures proposed by the MARVELS team were generally 
seen as adequate, including 24-hour access to a study doctor, availability of a 
research team member at the residential hostel, a sequence of monitoring visits to 
check for symptoms, and daily phone contact by the study doctor. With these 
procedures in place, most stakeholders felt reassured about safety. 
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“There is protection. If they see that a participant’s health has changed, they 
will rush them to the hospital, showing that there is help. So, we cannot have 
any concerns.” (Chief, FGD4)   
3.2.4 Compensation and reimbursement  
Compensation of volunteers participating in HIS research was identified by all 
stakeholder groups as important for acceptability. Within this, many participants 
mentioned reimbursing HIS volunteers for transport costs (for example, to attend 
monitoring check-ups at the hospital), and compensation for time away from income-
generating activity. The latter was particularly important given the three-day 
residential stay. 
“If he earns 2,000 a day [about £2], then that 2,000, you need to cover it for 
those days he participates in your study” (CAG member, FGD3-Fup) 
Stakeholders also discussed compensation for risk. Some felt compensation for HIS 
participation would be higher than for other studies as they perceived HIS as higher 
risk: 
“For the HIS I am sure we would go for a bit higher looking at the risks 
associated.” (REC member, KII) 
However, others thought compensation should be similar to other studies, to avoid 
reducing recruitment for other studies or creating undue inducement. Concerns 
about undue inducement were mentioned by several stakeholders and considered a 
particular risk for less educated or lower-income groups.  
“Here in Malawi, we have a lot of people who are poor, and poverty might be 
one reason they join the study, because of the incentives. They completely 
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don’t understand the study, but because they want to make ends meet, they’ll 
just join.” (Medical student, FGD5) 
Views on the amount of reimbursement and compensation varied widely, with 
suggested figures ranging from 15,000 [about £15] to 300,000 [about £300] for the 3-
day residential stay, plus additional amounts covering transport for hospital visits. 
Often stakeholders found it hard to indicate specific amounts and suggested that 
compensation be determined by researchers based on standard practice and 
guidance. 
“I feel like every organisation has its way of providing incentives and it would 
also be best to look [at] what do other organisations recommend on the type 
of incentives you can give to someone when you are involving his life and his 
health.” (Medical Student, FGD5) 
In relation to how reimbursement and compensation should be given to volunteers, 
most stakeholders felt it should be spaced throughout the study, to cover costs as 
they arise, and so reduce burden, and to support retention.  
As well as compensation for time and burden, stakeholders indicated the importance 
of insurance and compensation in the event of severe adverse events. 
“As long as there is an agreement that you will take care of everything if the 
volunteers fall sick or die while participating, then we don’t have concerns.” 
(Chief, FGD4-Fup) 
3.2.5 Regulation  
Stakeholders emphasised the need for careful review and approval of any HIS in 
Malawi by research ethics committees (RECs) and other regulatory bodies such as 
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pharmacy, medicine, and poisons body (PMPB), to protect the safety of participants: 
“They have to give approvals to show that they have met the standards, and 
they are not bringing any kind of harm to these people.” (Medical student, 
FGD-Fup) 
However, participants involved in medical care and research expressed concerns 
over the lack of standard regulatory guidelines on HIS to guide the local regulatory 
bodies. 
“But also making sure that there are clear guidelines from the regulators […] 
because this will be the first study. I don’t know if our regulators have got 
guidelines to conduct this type of research” (Senior Clinician, KII) 
3.2.6 Community engagement 
Community engagement was considered by all stakeholders as a key component if 
HIS research is to be accepted in Malawi.  As previously described, the potential for 
negative community reactions and distrust in HIS was a key concern for all 
stakeholder groups. However, many emphasised that adequate community 
engagement to promote understanding could overcome this concern:   
“There should be enough awareness raising among everyone, so they know 
the importance of HIS. This will ensure they understand what will happen in 
the study and they will be able to explain to other people who might be 
creating stories about it.” (Religious leader, FGD6) 
Comments on community engagement focused on raising awareness, sharing 
information about HIS, and providing an opportunity for people to ask questions. 
However, a few stakeholders also mentioned more two-way engagement with 
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community input to HIS design, particularly seeking feedback from participants once 
HIS research begins. 
On approaches for community engagement, participants suggested a range of 
channels, including working with chiefs, community opinion leaders, and the media 
to reach potential participants and wider communities.  
“I think the channels to use are chiefs, CAG members, or churches. […] even 
radio and TV stations so that many people hear the information.” (CAG 
member, FGD3-Fup)  
Community stakeholders also emphasised the presence of a HIS scientist during any 
community engagement activity to respond to any questions and give clear 
information. 
“You may face challenges with lots of questions. As we (chiefs) are holding 
meetings, you [the scientist] should be present to explain things to people 
clearly.” (Chief, FGD) 
3.3 The acceptability of other types of HIS beyond pneumococcal studies  
The views above relate to HIS focused on pneumococcal carriage. Participants were 
also asked for views on the acceptability of HIS for other diseases that require 
different procedures. Stakeholders had mixed views about the acceptability of other 
types of HIS, particularly HIS, such as malaria or typhoid, that are more likely to 
cause symptoms or require a longer residential stay or quarantine.  
The higher likelihood of developing symptoms was seen by some stakeholders as a 
concern for safety, although others felt it could be justified by the high burden of the 
disease considered (for example, malaria) and acceptable with adequate medical 
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support, including close monitoring.  
“I think people will be more scared of the higher risks. But still more it’s worth 
doing it because like I said about malaria, there are a lot of people who are 
affected by malaria” (Medical student, FGD-Fup) 
A longer residential stay or quarantine was considered positive for safety (including 
protecting participants and stopping the spread of infection to the public), but 
stakeholders mentioned potential negative impacts on family and livelihoods and 
concerns around participant comfort. Reasonable compensation and clear 
information on the procedures were identified as preconditions for acceptability. 
“Let’s say the man is a breadwinner at home – staying for 20 days is difficult. 
[…]. In that situation, you will provide not only transport but consider an 
amount to match the income he is missing.” (CAG member, FGD-Fup) 
Several stakeholders suggested starting with pneumococcus and then gradually 
expanding to other, potentially more challenging, diseases if initial HIS go smoothly 
and produce useful findings. 
“Because this is just the first HIS research starting in Malawi, it might be a bit 
risky in general; but I think as we go along we will see that maybe it’s going on 
well with the experience and there will be no problems with other types.” 
(Frontline research staff, FGD-Fup). 
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4 Discussion 
Our findings suggest that pneumococcal HIS research could be acceptable in 
Malawi, provided certain conditions are met. Many stakeholders saw HIS as 
potentially beneficial for population health, but they also had concerns, particularly 
related to safety and community reactions. Acceptability depended on approaches to 
aspects such as inclusion criteria, compensation, medical support, and community 
engagement. Many of the conditions highlighted by stakeholders reflect those in 
existing guidance on HIS, and in ethical guidance on biomedical research in general 
in LMIC. In this section, we compare our findings to existing guidance and draw out 
implications. 
Many of the conditions for the ethical conduct of HIS proposed in existing guidance 
were discussed by stakeholders in Malawi. For example, stakeholders mentioned 
achieving an adequate level of informed consent, fair selection of volunteers, 
appropriate compensation, safety measures to minimise potential harms and 
discomforts, and robust community engagement [2, 4, 28, 29]. Stakeholder views 
helped to indicate what these principles might mean in the Malawian context. 
Informed and voluntary consent was seen by many participants as a central 
condition, and critical for ensuring HIS is ethical and a fair offer. The idea of 
providing information through flyers or websites (rather than face to face) was 
considered potentially valuable for supporting voluntary decisions but needed to be 
accompanied by opportunities for an in-person discussion. This approach is in line 
with suggestions that recruitment for HIS participants should involve the distribution 
of advertisements on flyers and posters, followed by a comprehensive information 
package and information meeting [29]. Using flyers as a first step in the information 
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chain could potentially miss people who are illiterate but who would be interested in 
taking part. Experience with other research in Malawi suggests that information 
about opportunities to participate in HIS would spread by word of mouth, so it may 
reach people unable to read flyers [20]. Inclusive forms of communication that reach 
all potential participants should be considered for future HIS, for example, ensuring 
providing engagement material in local languages. 
Importantly for study design, ensuring informed and voluntary consent depends on 
more than the recruitment process, and stakeholders discussed the impacts on the 
consent of inclusion criteria and compensation. 
In relation to inclusion criteria, stakeholder views reflected principles and potential 
tensions indicated in existing guidance. In particular, existing guidance notes the 
need to promote safety by potentially limiting participation to those with English or 
more education, but also the potential inequity of these exclusions [5, 30]. The 
compromise suggested by some participants in our research was to start with a 
narrower group of participants and potentially broaden inclusion criteria as 
experience with HIS grows. However, views varied, with some stakeholders 
prioritising safety and others equity (primarily community members, who might be 
excluded). Another concern highlighted by our participants in relation to limiting HIS 
to more educated groups was the need to focus on groups most affected by the 
target disease. This may partly reflect limited explanation during FGDs about the use 
of follow up on trials after HIS that test vaccines in a broader population. Further 
public engagement that explains the sequencing and discussed the extent to which 
relevant results can be achieved in non-target groups would help to consider and 
assess this concern. 
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A related angle not discussed in the HIS literature but of concern for some 
stakeholders in Malawi was the need for communities to perceive the study as 
relevant to them, not just for the results to be medically applicable; limiting inclusion 
was seen as potentially limiting wider community interest and support, and 
potentially future vaccine uptake. 
The restriction to healthy adults proposed in existing guidance [4, 29] was widely 
supported by stakeholders in Malawi, along with the need for careful screening [2, 
31]. The need for screening held a particular significance in the Malawian context 
where HIV rates are high, and status is often unknown [32]. Views on inclusion of 
people with HIV reflected the same tensions between safety, equity, and relevance 
seen with restrictions based on education and medical training: stakeholders 
recognised the need for people with HIV to have access to a vaccine that works for 
them, but also had concerns about adequate immunity. 
Views on compensation also reflected some of the principles and tensions in the 
literature [2, 7, 9, 33]. Some stakeholders felt HIS volunteers should receive higher 
amounts, in line with suggestions in some guidance [34]. However, other 
stakeholders were concerned about undue influence, a concern widely shared in 
literature [2, 13, 28] and of particular significance in LMIC contexts where poverty 
may increase the value of study compensation [10]. Existing research in Kenya 
shows compensation can be a key driver of participation [10], but other studies in 
Kenya suggest compensation did not involve undue influence, and also did not set a 
precedent – another concern for some stakeholders in Malawi [8]. While many 
stakeholders suggested amounts for financial remuneration, some talked about 
access to health care as a potential form of compensation, reflecting the costs of 
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accessing high quality (private sector) health care in Malawi. 
Stakeholder discussions of compensation often highlighted the impact of 
participation on livelihoods and households, reflecting a context where many people 
have minimal if any savings, no formal employment, and rely on daily earnings 
through small-trading or other self-employment. In this context, even a short break in 
work can have significant effects on household livelihoods. Restricting participation 
to more educated groups may mean participants are more likely to be in formal 
employment, such that this is less of a concern. However, impacts on household 
well-being should be discussed with potential participants during recruitment and 
assessed through future study monitoring. 
Many stakeholders suggested that compensation levels should be decided by the 
research community. In line with this, compensation levels for MARVELS will be 
discussed with the REC and based on recent guidelines for Malawi [35, 36]1, but 
ongoing monitoring to understand participant motivation will help to assess whether 
amounts and forms of compensation are appropriate. 
The need for medical support to minimise risks and protect participants from harm 
was widely discussed, reflecting concern for safety. Availability of adequate medical 
 
1 The National Commission for Science and Technology (NCST) (2019) provided 
guidelines on compensation suggest that: “The level of compensation for research 
participants be determined on a case-by-case basis and dependent on the nature 
and design of a study” [36]. Gordon et al. presented remuneration tables to guide 
researchers and regulators on ways to calculate compensation based on study time 
and burden [35]. 
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facilities in case of harm was a concern for participants, given the constrained 
resources of the health sector in Malawi and consequent impacts on access to timely 
and quality care. Participants were generally reassured by plans for regular 
monitoring of participant health, continuous access to clinicians, and the residential 
stay to facilitate quick hospital access; an approach used effectively for HIS in similar 
contexts [4].   
Community engagement is noted in some existing guidance on HIS but received 
heavy emphasis from stakeholders in Malawi. This emphasis on working with 
communities is seen in wider guidance on biomedical research in LMIC [2, 5, 10]. 
Stakeholders expected critical public reactions, at least initially, reflecting previous 
experience of public unrest and rumours affecting research in this context. 
Stakeholder views tended to emphasise providing explanations and informing the 
public, with an instrumental approach of using engagement to support the effective 
conduct of research. While sharing information will be part of public engagement, 
ongoing two-way dialogue is needed, as started through this consultation. This two-
way approach is core to guidance on public engagement in LMICs [37], and needed 
both to inform the acceptable design of future HIS and for the intrinsic value and 
ethical importance of public involvement.  
A key condition highlighted in existing guidance that any HIS study must have a 
strong rationale that can only be achieved through HIS, received less critical 
attention from our participants. A concern for the importance of research was 
reflected in numerous comments about the value of research on pneumonia. 
However, the need to use HIS rather than other study models was not questioned. 
Many benefits of pneumococcal HIS identified by stakeholders – such as addressing 
the high burden of pneumonia and improving vaccines – are not necessarily specific 
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to HIS research and might potentially be achieved through other types of 
pneumococcal research. This assumption that HIS was required may have reflected 
trust in the expertise of researchers and a lack of familiarity with different types of 
vaccine research among many stakeholders, combined with a description of the 
rationale for HIS within FGDs and limited explanation of alternative approaches. 
Similarly, it was assumed by almost all participants that HIS would lead to effective 
vaccines, with only one senior clinician pointing to potential uncertainty in study 
impacts. HIS are one step in a series of studies needed to bring new vaccines to the 
market, but HIS researchers need to maximise the potential for impact through 
focusing only on questions with public health importance [2, 13], and through 
engaging with academic, pharmaceutical and policy stakeholders to advance 
translation of findings and progress along the vaccine development pipeline. This 
includes promoting access to any future vaccines among research communities, in 
line with broader ethical obligations regarding post-trial access in LMICs[38]. 
Providing this clarity would be in line with proposals that HIS should have a publicly 
available rationale that includes explaining why HIS is needed rather than 
alternatives [4].   
Our assessment of acceptability is preliminary and subject to limitations. Participants 
were unfamiliar with HIS, and their views will have reflected the information provided 
during focus groups and interviews. While we sought to ensure information was 
adequate and neutral, the provision of alternative information or research conducted 
by people independent of MLW may have resulted in different findings. In addition, 
views are at this stage hypothetical, and perceptions may change when HIS starts. 
We plan to continue embedding social science in MARVELS and future HIS in 
Malawi to understand participant experiences and views of people who choose not to 
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take part, to develop our understanding of acceptability, enable ongoing adaptation 
of HIS study design to optimise acceptability and to inform discussions on ethical 
approaches to HIS in LMIC settings. 
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5 Conclusion 
This study was the first investigation of HIS research acceptability in Malawi. Our 
findings highlight a range of concerns and issues to consider in the design of HIS. 
Within MLW, the findings informed the decision to proceed with a pneumococcal HIS 
feasibility study and were used in the study design. Summarised findings were also 
shared with the Malawi national ethics committee to support their ethical review of 
the feasibility study, and with the MARVELS funder.  The findings highlight the 
importance of community and stakeholder engagement, both during initial 
consideration and design of HIS, and an ongoing dialogue to build mutual 
understanding and ensure any HIS research is acceptable.  
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Additional Files 
Additional File: Topic guides for focus groups and stakeholder interviews 
Description of the Additional File: As described in the methods section, we have 
included the topic guide that we used to conduct focus group discussions, 
stakeholder interviews and follow-up interviews.These topic guides were drafted at 
the outset of the study but used flexibly to respond to issues raised by participants 
and adapted and refined during the fieldwork in response to emerging findings and 
reflections on previous interviews. 
 
 
